Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 15/20 | 0.36 |
| ▸ | CNR1 | P21554 | 9/20 | 0.36 |
| ▸ | UGCG | Q16739 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.31 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972310 | 0.84 | CNR2 (0.43) | HCAR2SLC6A4CNR2CNR1PIK3CD | |
| SCHEMBL11972298 | 0.83 | HCAR2 (0.42) | HCAR2SLC6A4CNR2CNR1UGCG | |
| SCHEMBL11972203 | 0.82 | HCAR2 (0.41) | HCAR2SLC6A4CNR2CNR1UGCG | |
| SCHEMBL11971712 | 0.79 | HCAR2 (0.40) | HCAR2SLC6A4CNR2CNR1 | |
| SCHEMBL29718286 | 0.77 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL11972244 | 0.76 | DRD4 (0.45) | CNR2CNR1 | |
| SCHEMBL11971777 | 0.70 | CNR2 (0.65) | HCAR2SLC6A4CNR2CNR1 | |
| SCHEMBL11971686 | 0.70 | CNR2 (0.62) | HCAR2SLC6A4CNR2CNR1 | |
| SCHEMBL11972160 | 0.68 | CNR2 (0.66) | HCAR2SLC6A4CNR2CNR1 | |
| SCHEMBL11972113 | 0.67 | CNR2 (0.49) | HCAR2SLC6A4CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9944606-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-8778950-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | disclosed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | HCAR2 319/4885SLC6A4 4064/4885CNR2 2/4885 |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | HCAR2 297/4885SLC6A4 3386/4885CNR2 100/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | HCAR2 319/4885SLC6A4 4064/4885CNR2 2/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | HCAR2 319/4885SLC6A4 4064/4885CNR2 2/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | HCAR2 319/4885SLC6A4 4064/4885CNR2 2/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | HCAR2 297/4885SLC6A4 3386/4885CNR2 100/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | HCAR2 319/4885SLC6A4 4064/4885CNR2 2/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | HCAR2 319/4885SLC6A4 4064/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.